Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Depreciation & Amortization (CF) (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Depreciation & Amortization (CF) for 8 consecutive years, with $30074.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 4.42% to $30074.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $118325.0 through Dec 2025, down 62.89% year-over-year, with the annual reading at $117052.0 for FY2025, 2.8% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $30074.0 at Outlook Therapeutics, up from $29737.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $30074.0 in Q4 2025, with the low at $28801.0 in Q4 2024.